Articles tagged with Breast Cancer Cells
Researchers at MD Anderson Cancer Center have identified USP13, an enzyme that stabilizes the tumor-suppressor protein PTEN, preventing its destruction by the cell's proteasome machinery. This discovery provides a new avenue for treating cancers with low levels of PTEN.
Researchers at UNC School of Medicine have identified Engrailed 1 as a protein overexpressed in basal-like carcinomas, which can lead to chemotherapy resistance. A synthetic peptide designed by Adriana Beltran and colleagues can disrupt Engrailed 1's function, causing rapid cell death.
Researchers at LSUHSC discovered a combination of six natural compounds from vegetables, fruits, and spices killed 100% of breast cancer cells. The super cocktail suppressed cell growth by over 80%, inhibited invasion, and caused cell death without harming normal cells.
Manipulating protein PRH can hinder the ability of cancer cells to penetrate into neighboring environments, potentially preventing their spread. The findings suggest that PRH regulation of Endoglin may represent a novel method for controlling migration and treating multiple cancers.
A Penn study reveals that low levels of mitochondrial DNA in tumor cells from aggressive breast cancer patients can lead to the development of metastatic properties. The research, published in Oncogene, breaks ground in understanding cancer progression and may offer a biomarker for personalized treatment approaches.
Researchers at Johns Hopkins Medicine discovered that exemestane not only inhibits estrogen production but also protects cells from UV radiation, inflammation, and oxidative damage. The drug may have applications beyond breast cancer treatment.
A team of researchers has identified a family of enzymes crucial for cancer growth in p53 mutant cells. Targeting these enzymes with novel agents may prevent the growth of p53 mutant cancers, benefiting patients with breast, ovarian, lung, colorectal, and brain tumors. The study suggests that inhibiting Type 2 PIP kinases could shut do...
Breast cancer cells with high levels of microsomal glutathione S-transferase-1 (MGST-1) resistant to chemotherapy can be killed using nanoparticles carrying doxorubicin. This approach enhances the effectiveness of drug treatment while minimizing adverse reactions.
Researchers have developed a novel nanostructure that can carry multiple components for simultaneous detection, diagnosis, and targeted drug delivery to cancer cells. This Janus nanostructure has the potential to provide earlier diagnosis and more accurate targeting of cancer cells, reducing drug side effects.
Researchers found that metformin works differently in high- versus low-glucose conditions. High glucose levels reduce metformin's effectiveness, making it necessary to use a higher dose or explore glucose control measures.
A UCLA study has identified a biological clock embedded in the human genome that can accurately measure the age of diverse organs, tissues, and cell types. The clock found that some parts of the anatomy, like breast tissue, age faster than the rest of the body.
A new optical imaging technique can accurately differentiate between breast cancer subtypes and detect responses to treatment as early as two days after therapy administration. The technique, known as optical metabolic imaging (OMI), measures the metabolic activity in cancer cells and generates distinct signatures for different types o...
Researchers at Thomas Jefferson University found that an HDL receptor in breast cancer cells may be responsible for the increased risk and aggressiveness of breast cancer. Blocking this receptor could help treat the disease, according to Dr. Philippe Frank.
Researchers at the University of Cincinnati have discovered a biomarker, phosphatidylserine, that can be effectively targeted to kill pancreatic cancer cells. The use of a biotherapy consisting of saposin C and dioleoylphosphatidylserine combined in nanovesicles shows promising results in animal models.
Researchers at the University of Michigan have developed a microfluidic chip that can capture elusive circulating tumor cells from blood, supporting their growth for further analysis. This technology has the potential to revolutionize cancer diagnosis and treatment by providing accurate prognoses and testing treatment options on cultur...
Researchers have pinpointed the binding site that can cause increased spreading of breast cancer cells, leading to metastases. The study reveals a new biomarker for breast cancer diagnosis and treatment, with potential for customized medicine.
Researchers developed a microfluidic device to study cancer cell extravasation, the process by which cells escape blood vessels. The device revealed that most arrested cells are trapped and eventually squeeze through, with their nuclei escaping even earlier than expected. Understanding this process can help identify therapies to preven...
Researchers have developed an advanced method to identify proteins modified with ADP-ribosylation, shedding light on PARP inhibitor treatment for breast and ovarian cancers. The new analysis method enables optimized treatment with fewer side effects, offering improved cancer treatment options.
Researchers have found that immune cells known as macrophages may help make the breast more susceptible to cancer at certain stages of the menstrual cycle. Hormonal fluctuations around menstruation may impact immune defenses in breast tissue, increasing risk of breast cancer.
Researchers at University of Rochester Medical Center identified a compound, AZD6244, that counteracts tamoxifen's toxic effects on brain cells. The finding offers hope for preventing 'chemo brain' and its debilitating symptoms.
A recent study by Eva Maria Putz and colleagues at the University of Veterinary Medicine, Vienna has found that phosphorylation of a specific serine residue (ser-727) in the STAT1 protein regulates natural killer cell cytotoxicity. This regulation is crucial for tumor surveillance and preventing cancer development.
Scripps Florida scientists discover that angiomotin is required for Yap-mediated tumor growth, challenging earlier findings of its inhibitory role. The study sheds light on a previously unknown pathway regulating cancer progression.
A new study reveals blind mole-rats are highly resistant to carcinogens and have anti-cancer activity in fibroblast cell culture, unlike lab mice and rats. The findings suggest that hypoxia tolerance, longevity, and cancer resistance are tied together through evolutionary adaptations.
Researchers found that certain genes, such as CXCL12 and IGF1, make breast cancer cells more likely to survive in bone tissue by mimicking the environment of their preferred organ. This discovery could lead to new drugs that prevent cancer spread to bone or other organs.
A study of healthy women found that describing preinvasive breast cancer as a high-risk condition rather than cancer leads to more women opting for nonsurgical treatments. The study's results suggest that the terminology used to describe DCIS can significantly impact patients' perceptions of treatment alternatives.
Researchers at UC Berkeley discovered that inhibiting an enzyme can dramatically reduce tumor growth and aggressiveness in cancer cells. The study sheds light on the importance of lipids in cancer development and suggests a promising new target for cancer therapy.
Researchers linked stress gene ATF3 to the spread of breast cancer, finding that immune-system cells expressing ATF3 aid cancer's survival and movement. The study suggests ATF3 may be a master switch enabling cancer's growth and metastasis.
Researchers discovered that early pregnancy reduces mammary gland progenitor cells, which can divide into milk-producing cells, reducing the risk of breast cancer. The study aims to develop a protective treatment mimicking the effects of early childbearing.
Researchers discovered the OGF-OGFr axis can inhibit proliferation in human triple-negative breast cancer cells, reducing growth within 24 hours. The therapy also confers protection against paclitaxel treatment, a standard breast cancer therapy, and has minimal side effects.
Researchers at Duke University found that tumor microenvironment alterations promote cancer progression by altering signaling in tumor-associated immune cells. The study supports the use of TGF-β inhibitors to enhance therapy efficacy.
Scientists have identified a unique enzyme that is abundant in cancer cells but rare in normal adult tissues. By silencing this enzyme, researchers were able to stop the growth of cancer in laboratory mice without causing harm.
Researchers found that high dietary sugar acts together with oncogenes to increase insulin sensitivity specifically in tumor cells. A three-drug combination blocking sugar conversion, Ras/Src signaling, and Wingless/Wnt signaling substantially reduced tumor size and progression.
Researchers develop method to filter out cancer cells from cerebrospinal fluid to prevent brain metastasis and decrease complications. This technique may help treat breast cancer and other metastasizing cancers earlier and with potentially fewer drugs.
Researchers at Sanford-Burnham Medical Research Institute have identified a novel mechanism of action for SMIP004, which specifically kills prostate cancer cells by interfering with mitochondrial function. The compound's effects were found to be particularly promising for treating castration-resistant prostate cancer.
Researchers have found that elevated levels of a receptor protein called Ret are associated with lower survival rates in breast cancer patients. Inhibiting this protein may be a promising approach to treating the disease.
A University of Colorado study shows that luteolin, a common autism supplement, blocks progesterone's action but promotes estrogen-stimulated breast cancer growth. The findings highlight the need for caution when consuming flavonoid supplements, as their effects on the endocrine system are not yet fully understood.
Scientists have solved a key piece of the puzzle on how BRCA1 gene mutations predispose women to breast and ovarian cancers. The answer lies in the way estrogen rushes in to rescue damaged cells whose healthy functioning has been altered by oxidative stress.
Researchers found that ZEB1 gene enables basal-type breast cancer cells to convert into aggressive tumor-forming cancer stem cells. Luminal breast cancer cells, which are less aggressive, carry the gene but have it permanently shut down.
Researchers have identified microRNA-22 as a driver of both cancer onset and metastasis, particularly in breast cancer and blood cancers. The study suggests that inhibiting miR-22 through a 'decoy' method could offer a novel therapeutic option for treating these diseases.
Researchers at the University of East Anglia made a major advancement in understanding tissue development, finding that protein EB2 is a key regulator of tube-like structures inside cells. This discovery has important implications for cancers such as gut, breast and pancreatic cancer.
Researchers have developed a targeted viral therapy that selectively kills breast cancer stem cells and induces apoptosis without affecting normal stem cells. The therapy, which uses the mda-7/IL-24 gene, was shown to be effective in both cell culture and animal models, with no toxic effects on healthy cells.
Researchers found that medical specialists can identify abnormality in breast and cervical cancer images with high accuracy, outperforming random guessing. However, localizing the issue proves challenging even for experts.
Researchers have found that bazedoxifene can stop the growth of breast cancer cells, including those with resistance to current targeted therapies. The study suggests that bazedoxifene's unique mechanism of action may make it a viable treatment option for patients with advanced breast cancer.
Scientists discovered that a subset of normal breast precursor cells have dangerously short telomeres and display high DNA damage response localized at their chromosome ends. This suggests new indicators for identifying women at higher risk for breast cancer.
Researchers at Salk Institute discover that protein TGF-β can promote cancer growth and survival in premalignant cells, offering hope for new treatment methods. The study's findings suggest that novel treatments may be able to halt cancer development in these cells.
A study from Western University has identified the Numb-p53 pathway as a key mechanism underlying chemotherapy resistance in triple-negative breast cancer. By targeting this pathway, researchers hope to develop novel therapies that can sensitize cancer cells to chemotherapy.
Researchers at UEA have made a breakthrough in breast cancer research showing that an enzyme called MMP-8 could be acting as a locator to the immune system, which then becomes activated to attack tumors. The findings suggest that this enzyme may help explain why some patients with breast tumors experience better outcomes.
A compound found in plant-based foods like parsley and celery has been shown to re-educate cancer cells into normal cells, making them more susceptible to death. The study, led by Ohio State University researchers, suggests that apigenin can restore normal gene regulation, leading to increased cell death rates among breast cancer cells.
Researchers identified immune gene signatures that predict cancer recurrence in certain breast cancer types, such as basal-like or triple negative disease. These signatures can help doctors make informed treatment decisions and may lead to valuable new strategies in personalized medicine.
A team of Duke researchers has discovered a previously unknown molecular network that regulates cell death and contributes to breast cancer drug resistance. The study found that high levels of the protein MDM2 block cell death signals, leading to drug resistance in breast cancer cells treated with lapatinib.
Researchers found that Wip1 mutations can lead to the shortening of this protein, allowing cancer cells to circumvent p53's protective mechanisms. These mutations were detected in colorectal and breast cancer patients, suggesting they may be a new target for cancer treatment.
A recent study published at the 5th IMPAKT Breast Cancer Conference finds that gene expression tests can effectively tailor cancer treatments to individual patients, despite variability in tumor cell types and gene expression. The researchers analyzed 78 biopsies from 26 tumors and found that some genomic tests were more reliable than ...
A Johns Hopkins study found that suppressing a key gene, HMGA1, in tumor cells reduces their aggression and growth. The researchers hope to develop a new therapy based on this principle to treat tumors resistant to current drugs.
Scientists at the University of Michigan have decoded the molecular signals that enable cancer cells to spread throughout the body. By understanding how tumor cells recruit healing cells, researchers can now develop drugs to block these messages and prevent metastasis.
Cancer cells exhibit unique physical properties as they metastasize, including increased deformability and reduced oxygen consumption. This study provides new insights into the dynamics of cancer cell behavior, suggesting that these traits enable them to spread through the body.
A new pathway has been identified that enhances tamoxifen's effectiveness in treating basal-like breast cancer, a subtype resistant to treatment. The discovery involves targeting Cdc42 protein to restore normal function of c-Cbl and improve cancer cell death.
Researchers investigate mango's effects on blood sugar levels and inflammation in obese individuals, finding reduced blood sugar and anti-inflammatory properties. The findings support previous animal model results and suggest a positive effect of mango polyphenols on human health.
Researchers discovered metastasis stem cells in the blood of breast cancer patients, characterized by specific surface molecules CD44, CD47, and MET. These cells are associated with a poorer prognosis and may serve as a promising biomarker for disease progression.
LSUHSC researchers identify LKB1 and Nischarin as a functional duo that regulate breast cancer cell migration and tumor growth. The study provides insight into the molecular mechanisms of tumor suppressor genes.
Researchers have identified a novel surface marker called Cd1d to isolate mammary gland stem cells with unprecedented purity. This breakthrough allows for high-degree profiling of normal and cancer stem cells, potentially leading to the development of new breast cancer drug targets.